As HOS-FRα tumors grew aggressively without EC17 treatment, accelerating EC17 dose escalation at this CAR-T cell dose was safe (no CRS or body weight loss) and resulted in a significant delay in tumor growth within the first two cycles of treatment (Figure 9B). Here, FOLR1 is linked to neoplasm.